Cargando…

A23 Population level diversification of hepatitis C viral strains over time among people who inject drugs in Baltimore, MD

Hepatitis C virus (HCV) infection occurs in 30–90 per cent of people who inject drugs (PWID). Although cure rates can exceed 95 per cent, treatment access is limited and approximately 400,000 people die each year due to complications of chronic infection. A temporal analysis of cluster networks amon...

Descripción completa

Detalles Bibliográficos
Autores principales: Hackman, J, Falade-Nwulia, O, Mehta, S, Downing, Z, Kirk, G, Ray, S, Thomas, D, Laeyendecker, O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736091/
http://dx.doi.org/10.1093/ve/vez002.022
_version_ 1783450456081563648
author Hackman, J
Falade-Nwulia, O
Mehta, S
Downing, Z
Kirk, G
Ray, S
Thomas, D
Laeyendecker, O
author_facet Hackman, J
Falade-Nwulia, O
Mehta, S
Downing, Z
Kirk, G
Ray, S
Thomas, D
Laeyendecker, O
author_sort Hackman, J
collection PubMed
description Hepatitis C virus (HCV) infection occurs in 30–90 per cent of people who inject drugs (PWID). Although cure rates can exceed 95 per cent, treatment access is limited and approximately 400,000 people die each year due to complications of chronic infection. A temporal analysis of cluster networks among PWID can be used to inform strategies to interdict transmission. In Baltimore, PWID have been recruited for The AIDS Linked to the IntraVenous Experience (ALIVE) cohort. A demographic questionnaire was administered and recorded for baseline and recent participants. Viral RNA underwent PCR with primers targeting the core and envelope-1 protein (CE1) and sequenced via Sanger sequencing. Sequences with > 400 bp reads and Q-scores >370 were used for downstream analysis resulting in 322 ALIVE baseline participants (1988–9) and 548 recently diagnosed subjects enrolled approximately two decades later (2005–16). Cluster networks were rendered with a threshold of 4 per cent in MicrobeTRACE, and statistical analyses were performed in R Studio. Of the 1988–9 subjects, the majority (259/317, 81.7%) were a part of cluster. There were nine clusters and fifty-eight singletons, with two large clusters containing most sequences of genotype 1a (73.5%). Two decades later, a minority of recently diagnosed individuals (235/512, 44.1%) were part of a cluster. There were seventeen clusters with 286 singletons with two large clusters containing 1a genotype individuals (21.5%). Additional clustering was done by parsing the two datasets by subtype 1a (n = 714) and 1b (n = 151). The genotype 1a network demonstrates a majority, 65.8 per cent, of participants in clusters. Moreover, two large clusters can be observed with baseline participants towards the center and recent participants on the outskirts indicative of high linkage at baseline. The genotype 1b network produced a single large cluster but subclusters were observed. The sequences between the two time points co-mingled but subclusters were also observed. Interestingly, the two large clusters from 1988 to 1989 were still evident in the 2005–16 viral sequences. We observed greater cluster diversity in more recently diagnosed individuals, indicative of a less connected network of individuals sharing transmission risk, though major viral strains did persist over time in this cohort.
format Online
Article
Text
id pubmed-6736091
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-67360912019-09-16 A23 Population level diversification of hepatitis C viral strains over time among people who inject drugs in Baltimore, MD Hackman, J Falade-Nwulia, O Mehta, S Downing, Z Kirk, G Ray, S Thomas, D Laeyendecker, O Virus Evol Abstract Overview Hepatitis C virus (HCV) infection occurs in 30–90 per cent of people who inject drugs (PWID). Although cure rates can exceed 95 per cent, treatment access is limited and approximately 400,000 people die each year due to complications of chronic infection. A temporal analysis of cluster networks among PWID can be used to inform strategies to interdict transmission. In Baltimore, PWID have been recruited for The AIDS Linked to the IntraVenous Experience (ALIVE) cohort. A demographic questionnaire was administered and recorded for baseline and recent participants. Viral RNA underwent PCR with primers targeting the core and envelope-1 protein (CE1) and sequenced via Sanger sequencing. Sequences with > 400 bp reads and Q-scores >370 were used for downstream analysis resulting in 322 ALIVE baseline participants (1988–9) and 548 recently diagnosed subjects enrolled approximately two decades later (2005–16). Cluster networks were rendered with a threshold of 4 per cent in MicrobeTRACE, and statistical analyses were performed in R Studio. Of the 1988–9 subjects, the majority (259/317, 81.7%) were a part of cluster. There were nine clusters and fifty-eight singletons, with two large clusters containing most sequences of genotype 1a (73.5%). Two decades later, a minority of recently diagnosed individuals (235/512, 44.1%) were part of a cluster. There were seventeen clusters with 286 singletons with two large clusters containing 1a genotype individuals (21.5%). Additional clustering was done by parsing the two datasets by subtype 1a (n = 714) and 1b (n = 151). The genotype 1a network demonstrates a majority, 65.8 per cent, of participants in clusters. Moreover, two large clusters can be observed with baseline participants towards the center and recent participants on the outskirts indicative of high linkage at baseline. The genotype 1b network produced a single large cluster but subclusters were observed. The sequences between the two time points co-mingled but subclusters were also observed. Interestingly, the two large clusters from 1988 to 1989 were still evident in the 2005–16 viral sequences. We observed greater cluster diversity in more recently diagnosed individuals, indicative of a less connected network of individuals sharing transmission risk, though major viral strains did persist over time in this cohort. Oxford University Press 2019-08-22 /pmc/articles/PMC6736091/ http://dx.doi.org/10.1093/ve/vez002.022 Text en © Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access publication distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstract Overview
Hackman, J
Falade-Nwulia, O
Mehta, S
Downing, Z
Kirk, G
Ray, S
Thomas, D
Laeyendecker, O
A23 Population level diversification of hepatitis C viral strains over time among people who inject drugs in Baltimore, MD
title A23 Population level diversification of hepatitis C viral strains over time among people who inject drugs in Baltimore, MD
title_full A23 Population level diversification of hepatitis C viral strains over time among people who inject drugs in Baltimore, MD
title_fullStr A23 Population level diversification of hepatitis C viral strains over time among people who inject drugs in Baltimore, MD
title_full_unstemmed A23 Population level diversification of hepatitis C viral strains over time among people who inject drugs in Baltimore, MD
title_short A23 Population level diversification of hepatitis C viral strains over time among people who inject drugs in Baltimore, MD
title_sort a23 population level diversification of hepatitis c viral strains over time among people who inject drugs in baltimore, md
topic Abstract Overview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736091/
http://dx.doi.org/10.1093/ve/vez002.022
work_keys_str_mv AT hackmanj a23populationleveldiversificationofhepatitiscviralstrainsovertimeamongpeoplewhoinjectdrugsinbaltimoremd
AT faladenwuliao a23populationleveldiversificationofhepatitiscviralstrainsovertimeamongpeoplewhoinjectdrugsinbaltimoremd
AT mehtas a23populationleveldiversificationofhepatitiscviralstrainsovertimeamongpeoplewhoinjectdrugsinbaltimoremd
AT downingz a23populationleveldiversificationofhepatitiscviralstrainsovertimeamongpeoplewhoinjectdrugsinbaltimoremd
AT kirkg a23populationleveldiversificationofhepatitiscviralstrainsovertimeamongpeoplewhoinjectdrugsinbaltimoremd
AT rays a23populationleveldiversificationofhepatitiscviralstrainsovertimeamongpeoplewhoinjectdrugsinbaltimoremd
AT thomasd a23populationleveldiversificationofhepatitiscviralstrainsovertimeamongpeoplewhoinjectdrugsinbaltimoremd
AT laeyendeckero a23populationleveldiversificationofhepatitiscviralstrainsovertimeamongpeoplewhoinjectdrugsinbaltimoremd